We have previously reported that liver X receptor (LXR) agonist, TO901317, could significantly inhibit hepatic apolipoprotein M (apoM) expression. It has been reported that TO901317 could activate the ATP-binding cassette transporter A1 (ABCA1) that mediates cholesterol efflux to the lipid-poor apoAI, which is an essential step for the high-density lipoprotein (HDL) formation. It is unknown if ABCA1 may regulate hepatic apoM expression. In the present study, HepG2 cells were cultured with the synthetic LXR agonists, TO901317 or GW3965 in the presence or absence of ABCA1 antagonist, disodium 4,4′-diisothiocyanatostilbene-2,2′-disulfonate (DIDS). The mRNA levels of ABCA1, apoM and liver receptor homologue-1 (LRH-1) determined by the real-time RT-PCR. It demonstrated that both TO901317 and GW3965 could significantly enhance ABCA1 expression, and simultaneously, inhibit LRH1 expression. However, TO901317 alone could significantly inhibit apoM expression, while GW3965 alone did not influence apoM expression. ABCA1 antagonist, DIDS, have no effects on GW3965 induced upregulation of ABCA1 and downregulation of LRH1. However, apoM mRNA level was significantly decreased when the cells cultured with GW3965 together with DIDS. The present study demonstrated that apoM expression could be elevated by ABCA1 via the RXR/LXR pathway and LRH1 does not involve in the regulation of apoM by the activation of ABCA1, although the direct regulative pathway(s) between ABCA1 and apoM gene is still unknown yet.
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Abstract
We have previously reported that liver X receptor (LXR) agonist, TO901317, could significantly inhibit hepatic apolipoprotein M (apoM) expression. It has been reported that TO901317 could activate the ATP-binding cassette transporter A1 (ABCA1) that mediates cholesterol efflux to the lipid-poor apoAI, which is an essential step for the high-density lipoprotein (HDL) formation. It is unknown if ABCA1 may regulate hepatic apoM expression. In the present study, HepG2 cells were cultured with the synthetic LXR agonists, TO901317 or GW3965 in the presence or absence of ABCA1 antagonist, disodium 4,4′-diisothiocyanatostilbene-2,2′-disulfonate (DIDS). The mRNA levels of ABCA1, apoM and liver receptor homologue-1 (LRH-1) determined by the real-time RT-PCR. It demonstrated that both TO901317 and GW3965 could significantly enhance ABCA1 expression, and simultaneously, inhibit LRH1 expression. However, TO901317 alone could significantly inhibit apoM expression, while GW3965 alone did not influence apoM expression. ABCA1 antagonist, DIDS, have no effects on GW3965 induced upregulation of ABCA1 and downregulation of LRH1. However, apoM mRNA level was significantly decreased when the cells cultured with GW3965 together with DIDS. The present study demonstrated that apoM expression could be elevated by ABCA1 via the RXR/LXR pathway and LRH1 does not involve in the regulation of apoM by the activation of ABCA1, although the direct regulative pathway(s) between ABCA1 and apoM gene is still unknown yet.
The detailed mechanism needs further investigation.
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Keywords: ATP-Binding cassette transporters; Apolipoprotein M; Liver Receptor Homolog-1; Liver X receptor Apolipoprotein M (apoM), one of the most recently discovered plasma apolipoproteins, is mainly associated with high density lipoproteins (HDL), with only a small proportion located in low density lipoprotein (LDL) and very low density lipoprotein (VLDL) particles [1] . Human apoM is exclusively expressed in the hepatocytes in liver and tubular epithelial cell in kidney, and small amounts were also found in fetal liver and fetal kidney [2] . Luo, et al., [3] demonstrated that apoM could also be abundantly expressed in human colorectal tissues, although the pathophysiological importance of this expression and if it could influence plasma apoM pool are unknown. Wolfrum, et al., [4] demonstrated that apoM, by influencing preβ-HDL formation, being an important regulator of HDL metabolism in vivo, which could influence cholesterol efflux and the susceptibility of atherosclerosis. They elucidated the molecular mechanism by which apoM affects HDL particle size and to exploit a possible new pathway for therapeutic strategies aiming to reduce the development or progression of atherosclerosis [4] . ApoM mRNA levels could be regulated by many intracellular and extracellular factors, including platelet activating factor (PAF), insulin, leptin, transforming growth factor-beta (TGF-β), epidermal growth factor (EGF), hepatic growth factor (HGF), etc., although the function of apoM is unknown yet [5, 6, 7, 8, 9, 10, 11] . Further investigating the regulation of hepatic apoM expression may explore the pathophysiological functions of apoM in vivo. 5 Liver X receptor (LXR) was initially identified as orphan member of the nuclear receptor superfamily that forms obligate heterodimers with retinoid X receptor (RXR) [12] . LXR-RXR can be activated by the endogenous oxysterols and by synthetic agonists such as T0901317 and GW3965 [13, 14] . LXR has been established to regulate intracellular cholesterol levels by transactivating the expression of ATP-binding cassette transporter A1 (ABCA1), which modulates cholesterol efflux and mediates reverse cholesterol transport from peripheral tissues [15] . It is still unknown if ABCA1 regulates hepatic apoM expression. In the present study, we examined effects of LXR agonists on ABCA1 activation in relation to the regulation of apoM expression HepG2 cells. Table 1 ). The quality of the RNA samples was determined by the absorbance measurements at 260/280 nm. According to the manufacturer's instructions of the first strand cDNA synthetic kit, 2μg total RNA was reverse transcribed to cDNA. The real-time PCR reaction for each gene was performed in a 25μL volume, in a glass capillary, containing 0.1μL 100mM each primer and probe, 2μL cDNA, 2.5μL 10 × buffer, 1.5μL MgCl 2 (25mM), 0.5μL dNTP (10mmol/L), 7 and Taq 
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Results
As shown in figure 1 , GW3965 could significantly increase ABCA1 mRNA levels and, at meanwhile, decrease LRH1 mRNA levels, which was dose dependent (Fig. 1) .
When the cells cultured with GW3965 at 10µM the ABCA1 mRNA level increased 8 by 15-times and LRH1 mRNA level decreased by more than 50%. However, apoM mRNA level was not significantly influenced in the cells after cultured with GW3965
( Fig. 1) . DIDS, an ABCA1 antagonist, have no statistical significant influence on GW3965 induced upregulation of ABCA1 and downregulation of LRH1 (Fig. 2 ).
Interestingly, apoM mRNA level was significantly decreased when the cells cultured with GW3965 together with DIDS (Fig. 2) . TO901317 could also enhance ABCA1 expression and suppress LRH1 expression in HepG2 cells (Fig. 3) . Moreover, it could also significantly inhibit apoM expression (Fig. 3) . When cells cultured with TO901317 together with DIDS, ABCA1 mRNA levels were even higher than cells cultured with TO901317 alone, but TO901317 induced inhibition of LRH1 was disappeared (Fig. 3) . ApoM mRNA level was decreased even more when the cells cultured with TO901317 together with DIDS (Fig. 3) .
Discussion
ABCA1, an integral membrane protein consisting of 12 transmembrane domains and two-ATP-binding domains, functions as a key role for the intracellular cholesterol efflux [16] . Mutations in the ABCA1 gene result in the Tangier disease (TD) [17, 18] .
ABCA1 promotes efflux of phospholipids and cholesterol to the lipid-poor apoAI in a process that involves the direct binding of apoAI to the transporter [19] . Many factors, including cAMP, sterols, cis-retinoic acid, peroxisome proliferator-activated receptor (PPAR) agonists, interferon-γ (IFN-γ) and LXR agonist could regulate ABCA1 expression [20] , further influences cholesterol efflux to apoAI. ApoM is one of the 9 last discovered apolipoproteins that is also involved in the HDL formation. It is still unknown if moderation of ABCA1 may influence hepatic apoM expression. Lacking apoM expression in the Tcflα−/− (hepatic nuclear factor 1α) mice or in apoM siRNA-injected mice leads to the formation of unusual large-sized HDL1 particles and the disappearance of prebeta HDL in plasma, suggesting that apoM may also play an important role in the HDL metabolism, particularly with regard to the formation and/or catabolism of prebeta HDL [4] . The formation of prebeta HDL has been known to be important for the reverse cholesterol transport. Overexpression of human apoM in mice increases HDL cholesterol concentrations, while apoM deficiency is associated with lower HDL cholesterol concentrations [21] . Ventenclef, et al., [9] reported that LRH-1 could directly regulate human and mouse apoM transcription by binding to an LRH-1 response element（5′CAAGG3′）located in the proximal apoM promoter region. Our previous studies demonstrated that the synthetic LXR agonist, TO901317, could downregulate hepatic apoM expression in vivo and in vitro [11] , which was confirmed by Calayir, et al. [22] . A hormone response element (HRE) that presents in the proximal apoM promoter could mediate apoM gene transcription by ligands of hormone nuclear receptor superfamily, such as HNF-4α, heterodimers of RXRα with retinoic acid receptor (RAR), thyroid hormone receptor β (TRβ) and liver X receptor (LXR) [22] . Moreover, it has been reported that TO901317 is a dual FXR/LXR agonist that activates the FXR more efficiently than its natural ligand, the bile acids CDCA chenodeoycholic acid (CDCA) [13, 23] , and have been demonstrated that the suppression of apoM by bile acids and the synthetic FXR agonist is most 10 likely mediated by FXR-SHP-LRH1 cascade [9] . Mitro, et al., [23] demonstrate that GW3965 does not activate FXR but LXR. Venkateswaran, et al., [24] suggest a model in which activation of LXRs by oxysterols in response to cellular sterol loading leads to induction of the ABCA1 transporter and the stimulation of lipid efflux to extracellular acceptors. Repa, et al., [25] identify the heterodimer of LXR/RXR on the upregulation of ABCA1 expression. The responsible control element was mapped to an imperfect direct repeat of the nuclear receptor half-site TGACCT separated by four bases (DR-4) that binds LXR/RXR heterodimers [26] . Those studies suggest that ABCA1 is one of the targets of LXR.
Our results show that LXR agonist GW3965 could significantly upregulate 
